| pubmed-article:15902285 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C0024301 | lld:lifeskim |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C0079744 | lld:lifeskim |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C1510411 | lld:lifeskim |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
| pubmed-article:15902285 | lifeskim:mentions | umls-concept:C0439801 | lld:lifeskim |
| pubmed-article:15902285 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15902285 | pubmed:dateCreated | 2005-7-21 | lld:pubmed |
| pubmed-article:15902285 | pubmed:abstractText | The role of TP53 mutation in transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL) was examined in a panel of 91 lymph node biopsies derived from 29 patients pre- and post-transformation. The entire TP53 coding sequence was screened and immunocytochemistry performed to determine expression of p53 and its key regulator MDM2. A total of 10 mutations were detected in eight patients (28%), although none were present at FL diagnosis. Mutations were not detected solely at the time of transformation; in three patients, mutated TP53 arose in at least one antecedent FL sample (6 months, 2.5 years and 4 years prior to transformation). Loss of heterozygosity at the TP53 locus occurred in 2/20 informative patients (only in t-FL samples). p53 staining was positive in 82% (9/11) of available biopsies with a missense mutation, and negative in 71% (45/63) with wtTP53. MDM2 expression was significantly higher in t-FL samples (mean 72% positive; 95% confidence interval (95% CI) 68-76%) than FL (mean 58% positive; 95% CI 54-62%) (P<0.001) but did not correlate with TP53 status. TP53 mutation has only a limited role in the transformation of FL, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent and may provide a more rational therapeutic target.. | lld:pubmed |
| pubmed-article:15902285 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15902285 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15902285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15902285 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15902285 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15902285 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:TaylorCC | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:ListerT ATA | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:DaviesA JAJ | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:LeeA MAM | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:IqbalSS | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:NortonA JAJ | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:GoffL KLK | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:FitzgibbonJJ | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:CalaminiciMM | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:Cuthbert-Heav... | lld:pubmed |
| pubmed-article:15902285 | pubmed:author | pubmed-author:ClearA JAJ | lld:pubmed |
| pubmed-article:15902285 | pubmed:copyrightInfo | Leukemia (2005) 19, 1459-1465. | lld:pubmed |
| pubmed-article:15902285 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15902285 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:15902285 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15902285 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15902285 | pubmed:pagination | 1459-65 | lld:pubmed |
| pubmed-article:15902285 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:meshHeading | pubmed-meshheading:15902285... | lld:pubmed |
| pubmed-article:15902285 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15902285 | pubmed:articleTitle | A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. | lld:pubmed |
| pubmed-article:15902285 | pubmed:affiliation | Cancer Research UK Medical Oncology Unit, Bart's and The Royal London School of Medicine and Dentistry, London, UK. Andrew.J.Davies@cancer.org.uk | lld:pubmed |
| pubmed-article:15902285 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15902285 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:4193 | entrezgene:pubmed | pubmed-article:15902285 | lld:entrezgene |
| entrez-gene:7157 | entrezgene:pubmed | pubmed-article:15902285 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15902285 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15902285 | lld:entrezgene |
| lhgdn:association:20020 | lhgdn:found_in | pubmed-article:15902285 | lld:lhgdn |
| lhgdn:association:20039 | lhgdn:found_in | pubmed-article:15902285 | lld:lhgdn |
| lhgdn:association:45962 | lhgdn:found_in | pubmed-article:15902285 | lld:lhgdn |
| lhgdn:association:46251 | lhgdn:found_in | pubmed-article:15902285 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15902285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15902285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15902285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15902285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15902285 | lld:pubmed |
